Topic: How To Invest

Power Growth Investor Hotline – Friday, April 28, 2023

Article Excerpt

BOSTON SCIENTIFIC CORP., $52.12, is a buy. The company (symbol BSX on New York) develops and markets medical devices used in minimally invasive procedures. Its products are used for angioplasty (blood vessel repair), blood clot filtration, cardiac rhythm management, catheter-aided ultrasound imaging, and many other surgical procedures. It generates 60% of its sales in the U.S. and 40% internationally. In the three months ended March 31, 2023, Boston Scientific’s revenue rose 12.0%, to $3.39 billion from $3.03 billion a year earlier. Excluding one-time items, the company earned $673.0 million, or $0.47 a share, in the quarter. That was up 19.8% from $562.0 million, or $0.39. During the latest quarter, Boston Scientific received U.S. Food and Drug Administration (FDA) clearance to launch its LithoVue Elite Single-Use Digital Flexible Ureteroscope System. The company also completed the acquisitions of Apollo Endosurgery Inc. and a majority stake in Acotec, a Chinese medical technology company. The LithoVue Elite Single-Use Digital Flexible Ureteroscope System assists urologists in monitoring intrarenal…